- Recent Funding
- Founders
- Edward Chouchani
About Edward
Edward Chouchani is a co-founder and Director at Matchpoint Therapeutics, a company focused on precision small molecule medicines for immune diseases. He is also an Associate Professor at Dana-Farber Cancer Institute and Harvard Medical School, where his lab applies mass spectrometry and biochemical approaches to understand how metabolites regulate cellular function. His research has led to the discovery of mechanisms through which lactate regulates protein function and the development of covalent inhibitors.
Strengths: founder archetype
one sourced signal · hover a cell for it, click for the source
Why researcher
Edward Chouchani's career is deeply rooted in academic research, evidenced by his extensive publications, lab at Dana-Farber, and numerous awards for scientific contributions. He leverages this deep scientific expertise to co-found a therapeutics company based on his lab's discoveries.
The signals behind it 3
- Our work on the discovery of a biochemical mechanism through which lactate regulates protein function, cell cycle, and proliferation, is out today in @nature.Researcher · Technical builderX
- We developed a first-in-class covalent inhibitor for creatine kinases, using chemoproteomics to target a conserved active site cysteine.Researcher · Technical builderX
- Matchpoint Therapeutics launches, with Ed as Scientific Co-Founder, based on science developed in the Chouchani Lab.Researcher · Technical builder
L
Edward Chouchani | Researcher to Therapeutics Founder
Every tag links its source.
Network
Background
1
- Affiliation Faculty @DanaFarber @harvardmed @HHMINEWSX
Timeline, line by line 14
B- Shared a new paper and online resource from his lab on a mass spectrometry approach to nominate functional relationships between metabolites and proteins.Sep 17, 2025X
- Named an HHMI Investigator.Jul 2024L
- Published a paper describing a mechanism for succinate uptake by brown adipocytes in Nature Metabolism.Mar 2024L
- Shared a new paper on the discovery of MCT1 as a mediator of succinate uptake into brown adipocytes.Feb 20, 2024X
- Awarded the Mark Foundation Emerging Leader Award.Jan 2024L
- Awarded the Bodossaki Distinguished Young Scientist Award.Jun 2023L
- Published a paper in Nature on the discovery of a biochemical mechanism for lactate control over protein function.Mar 2023L
- Published a study in @nchembio on a first-in-class covalent inhibitor for creatine kinases.Feb 23, 2023X
- Awarded a 2023 Vilcek Prize for Creative Promise.Oct 2022L
- Matchpoint Therapeutics launches, with Ed as Scientific Co-Founder, based on science developed in the Chouchani Lab.Oct 2022L
- Named a 2021 Pew Scholar.Jun 2021L
- Awarded the 2021 Helmholtz Young Investigator in Diabetes (HeIDi) Award.May 2021L
- Awarded the 2021 Armen H. Tashjian Award for Excellence in Endocrine Research.May 2021L
In their words
6
- “There have been a lot of technological advances in the field of cysteine proteomics. Here, @burger_nils and I provide an overview of these techniques that are improving our understanding of protein regulation by cysteine modification. Check it out!”Discussing technological advances in cysteine proteomics and their impact on understanding protein regulation. · Feb 21, 2024X
- “We propose local plasma membrane pH gradients regulate systemic regulation by succinate.”Explaining a finding from his lab's new paper on succinate uptake. · Feb 20, 2024X
- “Very excited and grateful to @TheMarkFdn for their support of our work on a newly discovered protein modification by lactate, and its role in cancer! @DanaFarber @HarvardCellBio”Expressing gratitude for funding supporting research on lactate's role in cancer. · Jan 18, 2024X
- “This is a very special research environment and starting my lab here has been an exceptional experience. Come join us!!”Encouraging potential applicants for an Assistant Professor position at Dana-Farber & Harvard Cell Biology. · Aug 16, 2023X
- “We hypothesized that, instead of just being an end-product of glycolysis, lactate may serve as a metabolic signal in this context.”Introducing the hypothesis behind his lab's research on lactate's role in cellular proliferation. · Mar 15, 2023X
- “More generally, our results suggest that the identification of redox-sensitive cysteines could be a useful strategy for the pharmacological targeting of undrugged proteins.”Discussing the broader implications of his lab's work on covalent inhibitors for creatine kinases. · Feb 23, 2023X
Researched from public pages: press, interviews, the company's site and the founder's own posts. Each source logo links the page that states the row; anything we couldn't source is left out. The archetype is our reading of that record, from a fixed set so founders can be compared. Updated Oct 12, 2026.
The week's top funded startups and market insights, in your inbox every Monday.
Unsubscribe anytime · privacy